“Our goal is to treat patients on a more individualized basis, matching the right drugs with the right patients,” said Anil Potti, M.D., an oncologist and researcher in the DCCC and the IGSP. “The combination of these two methods, one of which uses the clinical description of patient’s breast cancer and the other which looks at gene expression at a molecular level in a patient’s tumor, may allow us to do that with unprecedented accuracy. This represents a robust approach to personalizing treatment strategies in patients suffering from breast cancer.”
The findings appear in the April 2, 2008 issue of the Journal of the American Medical Association. The study was funded by the Jimmy V Foundation, the American Cancer Society and the Emilene Brown Research Fund.
Researchers looked at almost 1000 breast tumor samples, and corresponding patient data, and applied existing technology -- a computerized system called Adjuvant! -- to assess clinical characteristics and make predictions of recurrence based on them. By then comparing gene expression in these tumor samples, the researchers were able to see specific genomic patterns among patients with aggressive cancers, and those whose cancers were less likely to recur.
“We knew from previous studies that Adjuvant! tends to overestimate disease recurrence in younger patients,” Potti said. “We hypothesized that genomic profiling could be a complementary tool that would more precisely define clinical outcomes, and could also help to aid in selecting the right drug for a given patient.”
By using the clinical and genomic tools together and cross-comparing data, the researchers were able to not only say that a particular patient has a “high” risk of recurrence, but they could be more specific; for instance, they could predict that a particular patient was 90 percent likely to see her cancer recur, Potti said.
“This is important because with this data, we might decide to treat this person more aggressively even than someone else who is considered ‘high risk’ but may have only a 60 percent likelihood of recurrence,” he said. “Moreover, we can identify specific options for chemotherapy in such patients as well, by correlating gene expression in a tumor with its response, or non-response, to certain chemotherapies.”
The findings have already been put into practice as part of several clinical trials at Duke for cancer patients. A tumor’s genomic make-up is being used to dictate the choice between a traditional chemotherapy regimen and an alternate drug that is more likely to benefit an individual patient. One such trial involving almost 300 patients with breast cancer is expected to start at Duke this spring.
Lauren Williams | EurekAlert!
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
17.08.2017 | Physics and Astronomy
17.08.2017 | Earth Sciences
17.08.2017 | Physics and Astronomy